HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐Effectiveness
Open Access
- 15 March 2009
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (6), 806-815
- https://doi.org/10.1086/597095
Abstract
Background.The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemKeywords
This publication has 39 references indexed in Scilit:
- Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health CenterJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Pre-exposure prophylaxis for HIV infection: what if it works?The Lancet, 2007
- Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trialThe Lancet, 2007
- Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trialThe Lancet, 2007
- A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily RegimenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 InfectionThe Journal of Infectious Diseases, 2005
- Rapid Communication: Acute Renal Failure Associated with Tenofovir: Evidence of Drug-Induced NephrotoxicityThe American Journal of the Medical Sciences, 2002
- Evaluation of Initial CD4+T Cell Counts in Individuals with Newly Diagnosed Human Immunodeficiency Virus Infection, by Sex and Race, in Urban SettingsThe Journal of Infectious Diseases, 2002
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- Five‐Hundred Life‐Saving Interventions and Their Cost‐EffectivenessRisk Analysis, 1995